申请人:HOFFMANN LA ROCHE
公开号:WO2015044075A1
公开(公告)日:2015-04-02
The present invention relates to compounds of formula I wherein Y is N or C-R1'; G is a 5 or 6-membered aromatic or heteroaromatic ring containing 0, 1, 2 or 3 heteroatoms, selected from the group consisting of phenyl, pyridinyl with different N-positions, imidazolyl, pyrazinyl, pyrimidinyl, thiophenyl, thiazolyl, pyrazolyl or thiadiazolyl, which are optionally substituted by 1, 2 or 3 substituents, selected from the group consisting of halogen, lower alkyl, lower alkoxy, lower alkoxy substituted by halogen or NRR'; R and R' are independently from each other hydrogen or lower alkyl, or may form together with the N atom to which they are attached a five or six membered saturated heterocyclic group which may contain an additional oxygen, NH, or N-lower alkyl group; R1 is hydrogen, halogen or lower alkyl substituted by halogen; R1' is hydrogen, halogen or lower alkyl substituted by halogen; R2 is hydrogen, lower alkyl, lower alkoxyalkyl, cycloalkyl or heterocycloalkyl; or R2 may form together with the closest carbon atom in group G a group (IA) for A being -CH2-, -CH2CH2, or -C(CH3)2-, R3 is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. It has been surprisingly been found that the compounds of general formula I are positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4), useful for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
本发明涉及符号I的化合物,其中Y为N或C-R1';G为含有0、1、2或3个杂原子的5或6元芳香或杂芳环,所选自苯基、带有不同N-位置的吡啶基、咪唑基、吡啶嗪基、嘧啶基、噻吩基、噻唑基、吡唑基或噻二唑基,这些基可以选择性地被1、2或3个卤素、低烷基、低烷氧基、被卤素或NRR'取代;R和R'彼此独立地为氢或低烷基,或者可以与它们连接的N原子一起形成一个含有额外氧、NH或N-低烷基的五元或六元饱和杂环基;R1为氢、卤素或被卤素取代的低烷基;R1'为氢、卤素或被卤素取代的低烷基;R2为氢、低烷基、低烷氧基烷基、环烷基或杂环烷基;或者R2可以与基团G中最近的碳原子一起形成一个(A为-CH2-、-CH2CH2或-C(CH3)2-)的基团(IA);R3为苯基或吡啶基,其中吡啶基中的N原子可能在不同位置;或者为药学上可接受的盐或酸加合盐,或为外消旋混合物,或为其对应的对映体和/或光学异构体和/或立体异构体。令人惊讶的是发现,一般式I化合物是代谢型谷氨酸受体4(mGluR4)的阳性变构调节剂(PAMs),对帕金森病、焦虑、呕吐、强迫症、自闭症、神经保护、癌症、抑郁症和2型糖尿病的治疗有用。